Utama › Kanser (semua jenis) › Michigan › Detroit
Kajian klinikal Kanser (semua jenis) di Detroit, MI
29 kajian untuk Kanser (semua jenis) sedang mencari peserta di lokasi dalam dan sekitar Detroit (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Mengambil pesertaFasa 3
- Barbara Ann Karmanos Cancer Center, Detroit
- Henry Ford Cancer Institute-Henry Ford Hospital, Detroit
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Mengambil pesertaFasa 3
- Karmanos Cancer Center ( Site 0108), Detroit
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Mengambil pesertaFasa 2
- Henry Ford Health Saint John Hospital, Detroit
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Mengambil pesertaFasa 2/3
- Karmanos Cancer Center Wayne State University, Detroit
Connect for Cancer Prevention Study (Connect)
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Henry Ford Health Systems, Detroit
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Mengambil pesertaFasa 1/2
- GSK Investigational Site, Detroit
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Mengambil pesertaFasa 1
- Henry Ford Cancer Institute, Detroit
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Mengambil pesertaFasa 1/2
- Henry Ford Hospital, Detroit
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Mengambil pesertaKajian pemerhatian
- Karmanos Cancer Institute, Detroit
Project: Every Child for Younger Patients With Cancer
Mengambil pesertaKajian pemerhatian
- Children's Hospital of Michigan, Detroit
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- Karmanos Cancer Institute, Detroit
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Mengambil pesertaFasa 3
- Henry Ford Health Saint John Hospital, Detroit
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Mengambil pesertaFasa 1/2
- Henry Ford Cancer Institute, Detroit
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Mengambil pesertaFasa 1
- Henry Ford Hospital, Detroit
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1
- Henry Ford Health System, Detroit
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- Henry Ford Hospital, Detroit
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Mengambil pesertaFasa 2
- Karmanos Cancer Center (Wayne State University), Detroit
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Mengambil pesertaFasa 1/2
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
Mengambil pesertaFasa 1
- GSK Investigational Site, Detroit
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
Mengambil pesertaFasa 1
- GSK Investigational Site, Detroit
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
Mengambil pesertaFasa 1/2
- Karmanos Cancer Institute, Detroit
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Mengambil pesertaFasa 1
- Henry Ford Cancer Institute, Detroit
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Mengambil pesertaFasa 1/2
- Henry Ford Health, Detroit
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
Mengambil pesertaFasa 1
- Karmanos Cancer Institute, Detroit
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
Mengambil peserta
- Karmanos Cancer Institute, Detroit
A Beta-only IL-2 ImmunoTherapY Study
Mengambil pesertaFasa 1/2
- Karmanos Cancer Institute, Detroit
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- Henry Ford Cancer Institute, Detroit
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Mengambil pesertaFasa 1/2
- Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center, Detroit
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
Mengambil pesertaKajian pemerhatian
- Henry Ford Health System, Detroit
Kajian Kanser (semua jenis) di bandar lain
- Houston, TX121 kajian
- New York City, NY109 kajian
- Boston, MA85 kajian
- Los Angeles, CA74 kajian
- Nashville, TN65 kajian
- Philadelphia, PA59 kajian
- Washington, DC58 kajian
- Durham, NC58 kajian
- Chicago, IL51 kajian
- Atlanta, GA49 kajian
- Seattle, WA49 kajian
- Arlington, VA48 kajian
Kajian lain di Detroit
- Kanser Paru-paru Bukan Sel Kecil44 kajian
- Kanser Payudara33 kajian
- Kanser Kolorektal26 kajian
- Kanser Ovari26 kajian
- Kanser Metastatik24 kajian
- Kanser Prostat22 kajian
- Kanser Endometrium21 kajian
- Kanser Paru-paru20 kajian
- Mieloma Pelbagai19 kajian
- Kanser Perut16 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher15 kajian
- Leukemia Mieloid Akut14 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.